Members of the metalloproteinase protein (ADAM) family are therapeutic targets in many solid tumors, ADAM9 mRNA expression is 8.8-fold higher in vestibular schwannomas compared with normal tissues, and the expression level of ADAM9 is significantly correlated with hearing loss in patients and may be a marker for judging tumor growth and invasion [87]. Here, ADAM9 is linked to neoplasm.